TO THE EDITOR Bullous pemphigoid (BP) is an immunemediated disease with significant morbidity and mortality (Roujeau et al., 1998; Joly et al., 2012) . Rituximab has been used to treat a number of immunemediated diseases including pemphigus vulgaris (Joly et al., 2007; Tony et al., 2011) . We administered rituximab (1,000 mg; day 0 and 14) to seven BP subjects with recalcitrant disease to determine the safety, efficacy, and mechanisms related to rituximab treatment response and relapse. Seven BP subjects with persistent disease activity despite X17.5 mg per day prednisone were studied (five female subjects; two male subjects; mean disease duration 3.2 years) ( Supplementary Table online ), in accordance with the Declaration of Helsinki Principles and the Institutional Review Board of Duke University.
Subjects were followed up for 12 months. Disease flares were defined as the development of any disease activity necessitating an increased dose of prednisone. All subjects tolerated the infusions well with no drug-related serious adverse events. All subjects experienced a cessation of new skin lesions and a prednisone dose of 25% of starting dose or 10 mg at 6 months. Total disease activity significantly improved at 6, 9, and 12 months compared with baseline (P ¼ 0.0156, Wilcoxon test). Two subjects experienced a flare of their disease activity at months 7 and 11.5.
Subjects were evaluated by ELISA for IgG anti-BP180 and anti-BP230 autoantibodies (MBL, Woburn, MA) and IgE anti-BP180 using the NC16A domain of BP180 as described (Messingham et al., 2009) . IgG anti-varicella zoster antibody levels (Trinity Biotech, Jamestown, NY) and serum B-cell activating factor (BAFF) levels (R&D Systems, Minneapolis, MN) were determined by ELISA. Analysis of peripheral blood B cells was conducted by flow cytometry as described (Levesque et al., 2009) .
Before rituxiamb treatment, six of seven subjects had serum IgG anti-BP180 antibodies (range: 40-3,556 U ml À 1 ), four of seven subjects had IgG anti-BP230 antibodies (range 14-73 U ml À 1 ), and five of seven subjects had IgE anti-BP180 antibodies (range: 2.6-164 U ml À 1 ) Supplementary Table online ). There was a significantly lower level of IgG anti-BP180 at 6 and 9 months compared with baseline (Po0.05, Wilcoxon test). A decrease in the levels of IgG anti-BP230 and IgE anti-BP180 was noted, but it was not statistically significant at any time point compared with baseline ( Figure 1 ). There were no significant differences in serum IgG anti-varicella zoster antibodies and total serum IgG and IgE levels after rituximab therapy compared with baseline ( Figure 1 ).
BAFF serum levels increased after rituximab treatment, peaking at month 9 at 3,454 pg ml À 1 (mean, range ¼ 387-5,287 pg ml À 1 ). In the two subjects who experienced disease flare, peak serum BAFF levels were lower than those in the five subjects who did not experience a disease flare (P ¼ 0.0476, Mann-Whitney test, months 3, 4, and 12; Figure 2 ).
Depletion of B cells was noted within 2 weeks after the first rituximab infusion and persisted until month 12. At base-
Analysis of B-cell phenotypes during B-cell recovery revealed that the proportion of B cells expressing naive or transitional (CD38 þ þ /IgD þ /CD27 À ) phenotypes was significantly increased (mean ¼ 73%) at month 12 compared with week 0 (mean ¼ 35%) (P ¼ 0.0234, Wilcoxon test), with a decrease in memory B-cell populations at month 12 (mean ¼ 17%) compared with baseline (mean ¼ 39%; Supplementary Figure S1 online). Analysis of B-cell subsets during B-cell recovery in subjects who flared revealed that there was a greater increase in the proportion of memory B cells and plasmablasts compared with baseline (P ¼ 0.0476, Mann-Whitney test) and a significantly lower proportion of transitional cells at months 9 and 12 when compared with those subjects who did not experience a clinical flare (P ¼ 0.0476, Mann-Whitney test) (Supplementary Figure S2a , b online).
We found that rituximab therapy for BP patients was associated with a decrease in autoantibody levels with a half-life of about 30 days, consistent with the half-life in the circulation of IgG. IgE anti-BP180 antibodies decline less with persistent autoantibodies during the follow-up period. The level of anti-varicella zoster IgG antibodies did not change, consistent with the presence of rituximab-resistant long-lived plasma cells. One interpretation of this finding would be that two populations of IgG autoantibodies exist, one arising from short-lived plasma cells associated with the pathogenesis of skin disease and a second nonpathogenic group produced by long-lived plasma cells. Taken together, this suggests that rituximab therapy results in disease control by decreasing B cells, which are the precursors of short-lived plasma cells that produce pathogenic antibodies.
Analysis of B cells during recovery in five subjects who showed a persistent clinical response to rituximab therapy was similar to what has been previously reported (Leandro et al., 2006; Mouquet et al., 2008) . Peripheral blood B cells in the subjects who flared had a higher percentage of memory B cells (30%) compared with subjects who did not flare (3%) and a decreased proportion of naïve and/or transitional B cells, as reported in some AR studies (Roll et al., 2008; Sellam et al., 2011) . We found that the two subjects who flared also had markedly lower peak serum levels of BAFF following rituximab treatment. Nagel et al. (2009) reported a similar increase in serum levels of BAFF after rituximab treatment in subjects with pemphigus; however, no relationship between serum BAFF levels and clinical response was reported. The blunted BAFF response in the patients who flared suggests that despite the lack of detectable B cells in the circulation, the total peripheral B-cell pool was not depleted (Lavie et al., 2007; Kreuzaler et al., 2012) . We hypothesize that the failure to deplete total peripheral B cells resulted in the persistence of B cells with autoantibody specificity, allowing for a quicker repopulation of memory and short-lived plasmablasts producing autoantibodies that resulted in disease flares.
We have shown that rituximab is a therapeutic option in patients with severe BP. All subjects achieved a significant reduction in disease activity and steroid dosage at 6 months, with remissions greater than 12 months in five subjects. In the two subjects who flared during the 12-month follow-up, there were lower peak BAFF levels and an increased proportion of memory B cells at the time of B-cell reconstitution, consistent with inadequate total B-cell depletion. These findings suggest that lower peak serum BAFF levels, before B-cell recovery, may predict an early relapse of blistering skin lesions and may be an indication for earlier retreatment with rituximab.
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